ES2662373T3 - Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG - Google Patents

Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG Download PDF

Info

Publication number
ES2662373T3
ES2662373T3 ES12736469.3T ES12736469T ES2662373T3 ES 2662373 T3 ES2662373 T3 ES 2662373T3 ES 12736469 T ES12736469 T ES 12736469T ES 2662373 T3 ES2662373 T3 ES 2662373T3
Authority
ES
Spain
Prior art keywords
capsule
mgbg
methacrylic acid
ethyl acrylate
acrylate copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12736469.3T
Other languages
English (en)
Spanish (es)
Inventor
John Mckearn
Jeremy Blitzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pathologica LLC
Original Assignee
Pathologica LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathologica LLC filed Critical Pathologica LLC
Application granted granted Critical
Publication of ES2662373T3 publication Critical patent/ES2662373T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/13—Amines containing three or more amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/10—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C251/12—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton being acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/78—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
ES12736469.3T 2011-01-19 2012-01-19 Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG Active ES2662373T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434269P 2011-01-19 2011-01-19
US201161434269P 2011-01-19
PCT/US2012/021853 WO2012100043A2 (en) 2011-01-19 2012-01-19 Controlled release oral pharmaceutical dosage forms comprising mgbg

Publications (1)

Publication Number Publication Date
ES2662373T3 true ES2662373T3 (es) 2018-04-06

Family

ID=46516367

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12736469.3T Active ES2662373T3 (es) 2011-01-19 2012-01-19 Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG

Country Status (10)

Country Link
US (4) US8858991B2 (enExample)
EP (1) EP2665471B1 (enExample)
CA (1) CA2825014C (enExample)
DK (1) DK2665471T3 (enExample)
ES (1) ES2662373T3 (enExample)
HU (1) HUE038543T2 (enExample)
NO (1) NO2665471T3 (enExample)
PL (1) PL2665471T3 (enExample)
PT (1) PT2665471T (enExample)
WO (1) WO2012100043A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121586B1 (en) 2007-03-09 2017-03-08 Pathologica LLC Mgbg for the regulation of osteopontin and the treatment of multiple sclerosis
WO2011009039A2 (en) 2009-07-16 2011-01-20 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
NO2665471T3 (enExample) 2011-01-19 2018-05-26
BR112015016189A8 (pt) 2013-01-08 2019-10-22 Pathologica Llc usos de metilglioxal bis (guanilhidrazona) (“mgbg”), uso de metilglioxal bis (guanilhidrazona) (“mgbg”) e um agente e composição farmacêutica
US10987368B2 (en) * 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
JP7402225B2 (ja) 2018-05-11 2023-12-20 ロード アイランド ホスピタル ヌクレオシド系逆転写酵素阻害剤を用いて関節障害を処置するための組成物および方法
EP3914604A4 (en) 2019-01-25 2022-10-19 Brown University COMPOSITIONS AND METHODS FOR TREATMENT, PREVENTION OR REVERSE OF AGE-RELATED INFLAMMATION AND DISEASE
WO2025075624A1 (en) * 2023-10-05 2025-04-10 Mirum Pharmaceuticals, Inc. Pharmaceutical compositions comprising maralixibat and uses thereof
US12296050B2 (en) 2023-10-05 2025-05-13 Mirum Pharmaceuticals, Inc. Pharmaceutical compositions comprising maralixibat and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201788A (en) 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
US5614557A (en) 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US4520031A (en) * 1981-06-01 1985-05-28 The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone
CA1338366C (en) 1984-12-26 1996-06-04 Algis Anilionis Efficient prokaryotic expression system
US5580715A (en) 1994-08-05 1996-12-03 The Regents Of The University Of California Diagnosis of cancer having clonal macrophage involvement
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US5698563A (en) 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US6169115B1 (en) 1998-05-22 2001-01-02 Rima Kaddurah-Daouk Use of aminoguanidine analogs for the treatment of diseases of the nervous system
US6544541B1 (en) 1999-06-02 2003-04-08 Cardiovascular Solutions, Inc. Devices and compounds for treating arterial restenosis
CA2400374A1 (en) 2000-02-18 2001-08-23 Adrian Gilbert Oral, nasal and pulmonary dosage formualtions of copolymer 1
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
US6991809B2 (en) * 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
WO2003016491A2 (en) 2001-08-15 2003-02-27 The Regents Of The University Of California Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
US7211602B2 (en) 2001-11-16 2007-05-01 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
EP1389480A1 (en) 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
EP1613263A4 (en) 2003-01-31 2007-11-28 Pathologica Llc MONITORING AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
CA2519211A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Release control compositions
GB2400318B (en) 2003-04-08 2005-08-10 Novartis Ag Pharmaceutical composition comprising an S1P receptor agonist
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20050113455A1 (en) 2003-10-22 2005-05-26 Bergeron Raymond J.Jr. Method and composition for amelioration of pain
US7445794B1 (en) * 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
US20060189546A1 (en) 2005-01-28 2006-08-24 Ajami Alfred M Compounds for treating autoimmune and demyelinating diseases
PL1916995T5 (pl) * 2005-07-29 2022-10-31 Stichting Groningen Centre For Drug Research Kontrolowany wartością ph impulsowy układ podawczy, sposoby przygotowania i zastosowanie
US8912214B2 (en) 2005-07-29 2014-12-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of Chk2 kinase inhibitors for cancer treatment
EP1937235B1 (en) * 2005-09-23 2015-07-01 Pathologica, LLC. Methods for treating viral infections using polyamine analogs
WO2007047408A2 (en) * 2005-10-12 2007-04-26 Pathologica, Llc. Promac signature application
US20110091418A1 (en) 2006-09-25 2011-04-21 Pathlogica, LLC Methods for treating viral infections using polyamine analogs
EP2164698A1 (en) 2007-03-09 2010-03-24 Sustainable Solutions, Inc. Regenerated cotton board material and method of manufacture
EP2121586B1 (en) 2007-03-09 2017-03-08 Pathologica LLC Mgbg for the regulation of osteopontin and the treatment of multiple sclerosis
WO2008148798A2 (en) * 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009018368A1 (en) 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010045265A1 (en) 2008-10-13 2010-04-22 Biovista, Inc. Compositions and methods for treating multiple sclerosis
CN102281870B (zh) * 2008-12-10 2015-03-04 安徽中人科技有限责任公司 新型控释组合物
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011009039A2 (en) * 2009-07-16 2011-01-20 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
EP2283830A1 (en) * 2009-07-23 2011-02-16 Actogenix N.V. Aqueous enteric capsule coating
EP2343075A1 (en) 2010-01-04 2011-07-13 Neurotec Pharma, S.L. Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
NO2665471T3 (enExample) 2011-01-19 2018-05-26
BR112015016189A8 (pt) 2013-01-08 2019-10-22 Pathologica Llc usos de metilglioxal bis (guanilhidrazona) (“mgbg”), uso de metilglioxal bis (guanilhidrazona) (“mgbg”) e um agente e composição farmacêutica

Also Published As

Publication number Publication date
EP2665471B1 (en) 2017-12-27
US8858991B2 (en) 2014-10-14
DK2665471T3 (en) 2018-03-19
US10881626B2 (en) 2021-01-05
PT2665471T (pt) 2018-03-21
CA2825014C (en) 2019-01-08
US20210085625A1 (en) 2021-03-25
HUE038543T2 (hu) 2018-10-29
WO2012100043A2 (en) 2012-07-26
US9668988B2 (en) 2017-06-06
CA2825014A1 (en) 2012-07-26
WO2012100043A3 (en) 2012-10-18
US20180050000A1 (en) 2018-02-22
NO2665471T3 (enExample) 2018-05-26
EP2665471A2 (en) 2013-11-27
PL2665471T3 (pl) 2018-06-29
EP2665471A4 (en) 2014-07-23
US20120269891A1 (en) 2012-10-25
US20140377345A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
ES2662373T3 (es) Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG
AU2016266049B2 (en) Pharmaceutical for oral delivery comprising MGBG and methods of treating disease
US20190117578A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
DK2605757T3 (en) Nalbuphine-based formulations and applications thereof
JP2023027103A (ja) システアミン感受性障害の治療方法
US20180360783A1 (en) Methods and compositions for treatment of demyelinating diseases
EP2468261A1 (en) Formulation of lacosamide
WO2015156581A1 (ko) 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
MX2007002417A (es) Composiciones de multiparticula farmaceuticas que comprenden acido micofenolico o sodio de micofenolato y composiciones de combinacion de rapamicina.
KR102690703B1 (ko) 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도
US10583087B2 (en) Pharmaceutical composition for oral administration
EP2646434B1 (en) Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
RS64394B1 (sr) Tablete pregabalina sa kontrolisanim otpuštanjem, postupak njihove proizvodnje i način upotrebe
AU2017203694B2 (en) Controlled release oral pharmaceutical dosage forms comprising MGBG
TWI859242B (zh) 嘧啶基胺基-吡唑化合物之修飾釋放調配物及治療方法
AU2012207334A1 (en) Controlled release oral pharmaceutical dosage forms comprising MGBG
HK1186098A (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
HK1186098B (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
TW202425985A (zh) 控制釋放型醫藥組成物
JP2021024841A (ja) プレガバリン含有医薬組成物
NZ749754B2 (en) Methods and compositions for treatment of demyelinating diseases